RNAC

RNAC is not a company you can value on fundamentals — it's a clinical-stage biotech whose entire worth rides on Descartes-08, an mRNA cell therapy in Phase 3 for myasthenia gravis and Phase 2 for myositis. Management states plainly it has 'not generated any revenue from product sales' and that its mRNA approach to autoimmune disease is 'an unproven approach.' The $400K of FY2025 revenue is residual collaboration/license income (down 99% YoY), so the 701.8x P/S is a meaningless artifact, not a valuation signal. The FY2021-22 revenue and the lone profitable year (FY2022 net income +$35.4M) belong to the old Selecta business that reverse-merged with Cartesian in Nov 2023; they do not describe the company you'd be buying today.

The balance sheet is the disqualifier. Stockholders' equity is negative $126M against $423M of liabilities (liabilities/equity -3.35x), and the accumulated deficit has reached $822M. FY2025 net loss was $130M with operating cash flow of -$73.9M, while cash fell 41% to $125M. R&D rose 29% to $58M as Phase 3 spend accelerates, so burn is climbing, not stabilizing. Management's own runway guidance — cash funds operations 'for at least the next 12 months' on assumptions that 'may prove to be wrong' — signals a financing need on the horizon, and it explicitly expects to fund itself through 'equity offerings, debt financings' that would dilute a share base already up 2.3% YoY.